

# LITERATURA

1. Lindblom U, Merskey H, Mumford JM, et al. Pain terms. A current list with definitions and notes on usage. Part II. *Pain* 1986; Suppl 3: S215-S221.
2. Fields HL, Martin JB. Pain: pathophysiology and management. In: Fauci AS, Braunwald E, Isselbacher KJ et al., eds. *Harrison's Principles of Internal Medicine*, 14th ed. New York: McGraw Hill, Vol. 1 1998; 53-8.
3. Garcia J, Altman RD. Chronic pain states: pathophysiology and medical therapy. *Semin Arthritis Rheum* 1997; 27:1-16.
4. Long DM. *Contemporary diagnosis and management of pain*. Newton, PA: Handbooks in Health Care Co., 1992.
5. Zagari MJ, Mazonson PD, Longton WC. Pharmacoeconomics of chronic nonmalignant pain. *Pharmacoeconomics* 1996;10: 356-77.
6. World Health Organization. *Cancer pain relief and palliative care. report of a WHO expert committee*. World Health Organization Technical Report Series, 2nd ed. Geneva, Switzerland: World Health Organization, 1996.
7. Morgan JP. American Opiophobia: customary underutilization of opioid analgesics. *Controversies in Alcohol and Substance Abuse* 1986:163-73.
8. Lander J. Fallacies and phobias about addiction and pain. *British Journal of Addiction to Alcohol & Other Drugs* 1990; 85(6): 803-9.
9. Zenz M, Willweber-Strumpf A. Opiophobia and cancer pain in Europe. *Lancet* 1993; 341 (8852): 1075-6.
10. Bonica JJ. Treatment of cancer pain: current status and future needs. In: Fields HL et al., eds. *Advances in pain research and therapy*. Vol. 9. New York: Raven Press, 1985; 589-616.
11. Taub A. Opioid analgesics in the treatment of chronic intractable pain of non-neoplastic origin. In: Kiathata LM, Collins D, eds, *Narcotic analgesics in anesthesiology*. Baltimore: Williams and Wilkins, 1982;199-208.
12. Portenoy RK, Foley KM. Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. *Pain* 1986; 25:171-86.
13. France RD, Urban BJ, Keefe FJ. Long-term use of narcotic analgesics in chronic pain. *Soc Sci Med* 1984;19:1379-82.
14. Newman RG. The need to redefine 'addiction'. *N Engl J Med* 1983; 308(18):1097-8.
15. Shaffer HJ. The most important unresolved issue in the addictions: conceptual chaos. *Subst Use Misuse* 1997; 32(11 ):1573-80.
16. Latham J, Davis BD. The socioeconomic impact of chronic pain. *Disabil Rehab* 1994;16: 39-44.
17. Astin M, Lawton D, Hirst M. The prevalence of pain in a disabled population. *Soc Sci Med* 1996; 42: 1457-64.
18. Volinn E. The epidemiology of low back pain in the rest of the world: a review of surveys in low- and middle-income countries. *Spine* 1997; 22(15):1747-54.
19. Wilson JF, Brockopp GW, Steger HG. Quality of life patterns in patients who have suffered chronic pain: results of a statewide survey. Presented at the American Pain Society Meeting; October 1992; San Diego.

20. Ferrell BA, Ferrell BR, Osterweil D. Pain in the nursing home. *J Am Geriatr Soc* 1990; 38: 409-14.
21. Henriksson C, Gundmark I, Bengtson A, Ek AC. Living with fibromyalgia: consequences for everyday life. *Clin J Pain* 1992; 8:138-44.
22. Hitchcock LS, Ferrell BR, McCafferty M. The experience of chronic non-malignant pain. *J Pain Symptom Manage* 1994; 9: 312-18.
23. Becker N, Thomsen AB, Olsen AK, Sjogren P, Bech P, Eriksen J. Pain epidemiology and health related quality of life in chronic non-malignant pain patients referred to a Danish multidisciplinary pain center. *Pain* 1997; 73: 393-400.
24. Webster BS, Snook SH. The cost of 1989 workers' compensation low back pain claims. *Spine* 1994; 19: 1111-5, discussion 1116.
25. Bolten W, Kempel-Waibel A, Pforringer W. Analysis of cost of illness of low back pain. *Medizinische Klinik* 1998; 93(6): 388-93.
26. Clinical Standards Advisory Group's Report on Back Pain. Epidemiology review: the epidemiology and cost of back pain. HMSO 1994.
27. Sheehan J, McKay J, Ryan M, Walsh N, O'Keefe D. What cost chronic pain? *Ir Med J* 1996; 89: 218-19.
28. Hagen N, Flynn P, Hays H, MacDonald N. Guidelines for managing chronic malignant pain: opioids and other agents. *Can Fam Physician* 1995; 41: 49-53.
29. Reidenberg MM, Portenoy RK. The need for an open mind about the treatment of chronic malignant pain. *Clin Pharmacol Ther* 1994; 55: 367-9.
30. Brena SF, Sanders SH. Opioid use in managing non-cancer pain: the cart before the horse. *APS Bull* 1991; 1: 7-8.
31. Brena SF, Sanders SH. Opioids in non-malignant pain: questions in search of answers. *Clin J Pain* 1991; 7: 342-5.
32. Portenoy RK. Opioid therapy for chronic non-malignant pain: current status. In: Fields HL, Liebeskind JC. *Progress in pain research and management*. Seattle: IASP Press, 1994; 247-87.
33. Portenoy RK. Opioid therapy for chronic non-malignant pain: a review of critical issues. *J Pain Symptom Manage* 1996; 11: 203-17.
34. Justins D. Non-malignant chronic pain. *Prescribers' J* 1993; 33: 259-66.
35. American Society of Anesthesiologists Task Force on Pain Management, Chronic Pain Section. Practice guidelines for chronic pain management. *Anesthesiology* 1997; 86: 995-1004.
36. North RB, Kidd DH, Zahurak M et al. Spinal cord stimulation for chronic, intractable pain: experience over two decades. *Neurosurgery* 1993; 32: 384-95.
37. LeDoux MS, Langford KH. Spinal cord stimulation of the failed back syndrome. *Spine* 1993; 18: 191-4.
38. Bel S, Bauer BL. Dorsal column stimulation (DCS): cost to benefit analysis. *Acta Neurochir* 1991; 52: 121-3.
39. Graziotti PJ, Goucke CR. The use of oral opioids in patients with chronic non-cancer pain: management strategies. *Med J Aust* 1997; 167: 30-4.
40. Flor H, Fydrich T, Turk DC. Efficacy of multidisciplinary pain treatment centres: a meta-analytic review. *Pain* 1992; 49: 221-30.
41. Pfingsten M, Hildebrandt J, Leibing E et al. Effectiveness of a multimodal treatment program for chronic low-back pain. *Pain* 1997; 73: 77-85.
42. Elkayam O, Itzhak BS, Avrahami E et al. Multidisciplinary approach to chronic back pain: prognostic elements of the outcome. *Clin Exp Rheumatol* 1996; 14: 281-8.
43. Flavell HA, Carrafa GP, Thomas CH, Disler PB. Managing chronic back pain: impact of an interdisciplinary team approach. *Med J Aust* 1996; 165: 253-5.
44. The use of opioids for the treatment of chronic pain. A consensus statement from the American Academy of Pain Medicine and the American Pain Society. *Pain Forum* 1997; 6(1 ): 77-9.
45. Pappagallo M, Heinberg LJ. Ethical issues in the management of chronic non-malignant pain. *Semin Neurol* 1997; 17: 203-11.
46. Portenoy RK. Chronic opioid therapy in non-malignant pain. *J Pain Symptom Manage* 1990; 5: S46-S62.
47. Schug SA, Merry AF, Acland RH. Treatment principles for the use of opioids in pain of non-malignant origin. *Drugs* 1991; 42: 228-39.
48. Bovill JG. Mechanisms of actions of opioids and non-steroidal anti-inflammatory drugs. *Eur J Anaesthesiol* 1997; 14 (Suppl 15): 9-15.
49. Carson JL, Strom BL, Morse ML et al. The relative gastro-intestinal toxicity of the nonsteroidal anti-inflammatory drugs. *Arch Intern Med* 1987; 147: 1054-9.

50. Eccles M, Freemantle N, Mason J for the North of England Non-Steroidal Anti-inflammatory Drug Guideline Development Group. North of England evidence based guideline development project: summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. *BMJ* 1998; 317: 526-30.
51. Lipman AG. Clinically relevant differences among the opioid analgesics. *Am J Hosp Pharm* 1990; 47 (Suppl 1 ): 7-13.
52. Byas-Smith MG, Max MB, Muri J et al. Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage 'enriched enrolment' design. *Pain* 1995; 60: 267-74.
53. Egbunike IG, Chaffee B. Antidepressants in the management of chronic pain states. *Pharmacotherapy* 1990; 10: 262-70.
54. Fields HL. *Pain*. New York: McGraw-Hill, 1987.
55. McOuay HJ, Tramer M, Nye BA et al. A systematic review of antidepressants in neuropathic pain. *Pain* 1996; 68: 217-27.
56. Max MB. Treatment of post-herpetic neuralgia: antidepressants. *Ann Neurol* 1994; 35 (Suppl): 50-3.
57. Max MB, Lynch SA, Muir J et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. *N Engl J Med* 1992; 326 (19): 1250-60.
58. British National Formulary. Number 34. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 1997.
59. McNairy SL, Maruta T, Ivnik RJ et al. Prescription medication dependence and neuropsychologic function. *Pain* 1984; 18: 169-77.
60. Maruta T, Swanson DW. Problems with the use of oxycodone compound in patients with chronic pain. *Pain* 1981; 11: 389-96.
61. Maruta T, Swanson DW, Finlayson RE. Drug abuse and dependency in patients with chronic pain. *Mayo Clin Proc* 1979; 54: 241-4.
62. Turner JA, Calsyn DA, Fordyce WE, Ready LB. Drug utilization pattern in chronic pain patients. *Pain* 1982; 12: 357-63.
63. Portenoy RK. Opioid therapy in the management of chronic back pain. In: Tollison CD, ed. *Interdisciplinary rehabilitation of low back pain*. Baltimore: Williams and Wilkins, 1989; 137-51.
64. Zenz M, Strumpf M, Tryba M. Long-term oral opioid therapy in patients with chronic nonmalignant-pain. *J Pain Symptom Manage* 1992; 7: 69-77.
65. Fordyce WE. On opioids and treatment targets. *APS Bull* 1991; 1: 34.
66. Coniam SW. Prescribing opioids for chronic pain in non-malignant disease. In: Twycross RG, ed. *The Edinburgh symposium on pain control and medical education*. London: Royal Society of Medicine International Congress and Symposium Series No. 149, 1989; 205-10.
67. Turk DC, Brody MC. What position do APS's physician members take on chronic opioid therapy? *APS Bull* 1992; 2: 1-5.
68. Turk DC, Brody MC, Okifuji EA. Physicians' attitudes and practices regarding the long-term prescribing of opioids for non-cancer pain. *Pain* 1994; 59: 201-8.
69. Melzack R. The tragedy of needless pain. *Sci Am* 1990; 262(2): 27-33.
70. Redmond DE Jr., Krystal JH. Multiple mechanisms of withdrawal from opioid drugs. *Ann Rev Neurosci* 1984; 7: 443-78.
71. Cox BM. Molecular and cellular mechanisms in opioid tolerance. In: Basbaum AI, Besson J-M, eds. *Towards a new pharmacotherapy of pain*. New York: John Wiley, 1991; 137-56.
72. Puttfarcken PS, Werling LL, Cox BM. Effects of chronic morphine exposure on opioid inhibition of adenylyl cyclase in 731 c cell membranes: a useful model for the study of tolerance at mu opioid receptors. *Mol Pharmacol* 1988; 33: 520-7.
73. Dourish CT, Hawley D, Iversen SD. Enhancement of morphine analgesia and prevention of morphine tolerance in the rat by the cholecystokinin antagonist L-364,718. *Eur J Pharmacol* 1988; 147: 469-72.
74. Tiseo PJ, Inturrisi CE. Attenuation and reversal of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist, LY274614. *J Pharmacol Exp Ther* 1993; 264: 1090-6.
75. Kolesnikov YA, Pick CG, Pasternack GW. N-nitro-L-arginine prevents morphine tolerance. *Eur J Pharmacol* 1992; 221 (2-3): 399-400.
76. Coyle N, Adelhardt J, Foley KM, Portenoy RK. Character of terminal illness in the advanced cancer patient: pain and other symptoms in the last 4 weeks of life. *J Pain Symptom Manage* 1990; 5: 83-93.
77. Hill HF, Chapman CR, Kornell JA et al. Self-administration of morphine in bone marrow transplant patients reduces drug requirement. *Pain* 1990; 40: 121-9.

78. Glynn CJ, McOuay H, Jadad AR, Carroll D. Response to controversy corner: Opioids in non-malignant pain: questions in search of answers'. *Clin J Pain* 1991; 7: 346.
79. Schug SA, Zech D, Grond S et al. A long-term survey of morphine in cancer pain patients. *J Pain Symptom Manage* 1992; 7: 259-66.
80. Colpaert FC, Niemeegers CJE, Janssen PAJ, Maroli AN. The effect of prior fentanyl administration and of pain on fentanyl analgesia: tolerance to and enhancement of narcotic analgesia. *J Pharmacol Exp Ther* 1980; 213: 418-26.
81. Weissman DE, Haddox JD. Opioid pseudoaddiction -An iatrogenic syndrome. *Pain* 1989; 36(3): 363-6.
82. Medina JI, Diamond S. Drug dependency in patients with chronic headache. *Headache* 1977; 17: 12-14.
83. Porter JH, Jick J. Addiction rare in patients treated with narcotics. *N Engl J Med* 1980; 302:123.
84. Perry S, Heidrich G. Management of pain during debridement: a survey of US burn units. *Pain* 1982;13: 267-80.
85. Vaino A, Ollila J, Matikainen E et al. Driving ability in cancer patients receiving long-term morphine analgesia. *Lancet* 1995; 346: 667-70.
86. Menefee LA, Pappagallo M, Quatrano-Piacentini AL, Haythornthwaite JA. Psychological effects of long-acting opioids in the treatment of failed back syndrome. Presented at the 14th Annual Meeting of the American Pain Society, 1995.
87. Bruera E, Macmillan K, Hanson JA, MacDonald RN. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. *Pain* 1989; 39:13-16.
88. Haythornthwaite JA, Menefee LA, Quatrano-Piacentini AL, Pappagallo M. Outcome of chronic opioid therapy for non-cancer pain. *J Pain Symptom Manage* 1998;15:185-94.
89. Zacny JP, Wilson PR. Opioids and chronic pain. *Clin J Pain* 1998;14(1 ): 89-90.
90. Romano J, Turner J. Chronic pain and depression: does the evidence support a relationship? *Psychol Bull* 1985; 97:18-34.
91. Haythornthwaite JA, Sieber WJ, Kerns RD. Depression and the chronic pain experience. *Pain* 1991; 46:177-84.
92. Moulin DE, Iezzi A, Amireh R et al. Randomised trial of oral morphine for chronic non-cancer pain. *Lancet* 1996; 347:143-7.
93. Zech DFJ, Grond SUA, Lynch J et al. Transdermal fentanyl and initial dose-finding with patient-controlled analgesia in cancer pain - a pilot study with 20 terminally ill cancer patients. *Pain* 1992; 50: 293-301.
94. Korte W, De Stoutz N, Morant R. Day-to-day titration to initiate transdermal fentanyl in patients with cancer pain: short- and long-term experiences in a prospective study of 39 patients. *J Pain Symptom Manage* 1996;11 (3):139-46.
95. Ahmedzai S, Brooks D on behalf of the TTS-fentanyl comparative trial group. Transdermal fentanyl versus sustained release oral morphine in cancer pain: preference, efficacy and quality of life. *J Pain Symptom Manage* 1997;13: 254-61.
96. Donner B, Zenz M, Strumpf M, Raber M. Long-term treatment of cancer pain with transdermal fentanyl. *J Pain Symptom Manage* 1998;15(3):168-75.
97. Donner B, Zenz M, Tryba M, Strumpf M. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. *Pain* 1996; 64(3): 527-34.
98. Bruera E, Sloan P, Mount B et al. A randomized, double-blind, double-dummy, crossover trial comparing the safety and efficacy of oral sustained-release hydromorphone with immediate-release hydromorphone in patients with cancer pain. *J Clin Oncol* 1996;14:1713-7.
99. Hanks GW, Twycross RG, Lloyd JW. Unexpected complication of successful nerve block. *Anaesthesia* 1981; 36: 37-9.
100. McOuay HJ. Potential problems of using both opioids and local anaesthetic [letter]. *Br J Anaesth* 1988; 61:121.
101. Wall PD. Neuropathic pain [editorial]. *Pain* 1990; 43: 267-8.
102. DelleMijn PLI, Vanneste JAL. Randomised double-blind active-placebo-controlled crossover trial of intravenous fentanyl in neuropathic pain. *Lancet* 1997; 349: 753-8.
103. The use of opioids for the treatment of chronic pain - a consensus statement from the American Academy of Pain Medicine and the American Pain Society. *Clin J Pain* 1997;13(1 ): 6-8.
104. Ripamonti C, Bruera E. Adverse effects of opioids in cancer patients. Guidelines for treatment. *CNS drugs* 1997; 8: 21-37.
105. Ferrell B, Wisdom C, Wenzl C et al. Effects of controlled-release morphine on quality-of-life for cancer pain. *Oncol Nurs Forum* 1989;16: 521-6.

106. Cherry DA, Gourlay GK. Pharmacological management of chronic pain: a clinician's perspective. *Agents Actions* 1994 ; 42:172-4.
107. Woods JH, Winger G. Opioids, receptors and abuse liability. In: Meltzer HY, ell. *Neural blockade in clinical anaesthesia and management of pain*, 2nd ell. Philadelphia: Lippincott, 1987; 885-98.
108. Allan L, Hays H, Jensen N-H et al. Evidence for better analgesia with transdermal fentanyl in chronic pain treatment: comparison with sustained release morphine in a crossover efficacy, safety and quality of life trial. Abstract presented at *Pain Management: Towards 2000*; November 1998; Israel.
109. Bouckoms AJ, Masand P, Murray GB et al. Chronic non-malignant pain treated with long-term oral narcotic analgesics. *Ann Clin Psychiatry* 1992; 4:185-92.
110. Tennant FS, Uelman GF. Narcotic maintenance for chronic pain: medical and legal guidelines. *Postgrad Med* 1983; 73: 81-94.
111. Wan Lu C, Urban B, France RD. Long-term narcotic therapy in chronic pain. Presented at the *Canadian Pain Society and American Pain Society Joint Meeting*; 1988; Nov 10-13; Toronto.
112. Arkininstall W, Sandier A, Goughnour B et al. Efficacy of controlled-release codeine in chronic non-malignant pain: a randomized, placebo-controlled clinical trial. *Pain* 1995; 62:169-78.
113. Rowbotham MC. Chronic pain: from theory to practical management. *Neurology* 1995; 45 (Suppl 9): 5-10.
114. Kupers RC, Konings H, Adriaensen H, Gybels JM. Morphine differentially affects the sensory and affective pain ratings in neurogenic and idiopathic forms of pain. *Pain* 1991; 47: 5-12.
115. Benedetti F, Vighetti S, Amanzio M, et al. Dose-response relationship of opioids in nociceptive and neuropathic postoperative pain. *Pain* 1998; 74: 205-11.
116. Rowbotham MC, Lori A, Reisner-Keller LA, Fields HL. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. *Neurology* 1991; 41:1024-8.
117. Jacobson L, Chabal C, Broly MC et al. A comparison of the effects of intrathecal fentanyl and lidocaine on established post-amputation stump pain. *Pain* 1990; 40:137-42.
118. Gourley GK. Long term use of opioids in chronic pain patients with non terminal disease states. *Pain Rev* 1994;1: 62-76.
119. Villiger JW, Ray LJ, Taylor KM. Characteristics of [3H] fentanyl binding to the opiate receptor. *Neuropharmacology* 1983; 22: 447-52.
120. Donner B, Zenz M. Transdermal fentanyl: a new step on the therapeutic ladder. *Anticancer Drugs* 1995; 6 (Suppl 3): 39-43.
121. Roy SD, Flynn GL. Transdermal delivery of narcotic analgesics - pH, anatomical, and subject influences on cutaneous permeability of fentanyl and sufentanil. *Pharm Res* 1990; 7: 842-7.
122. Twycross R. *Symptom management in advanced cancer*, 2nd ell. Oxon: Radcliffe Medical Press Ltd, 1997; 39.
123. Scholz J, Steinfath M, Schulz M. Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil: an update. *Clin Pharmacokinet* 1996; 31: 275-92.
124. Jeal W, Benfield P. Transdermal fentanyl: a review of its pharmacological properties and therapeutic efficacy in pain control. *Drugs* 1997; 53:109-38.
125. Megens AAHP, Artois K, Vermeire J et al. Comparison of the analgesic and intestinal effects of fentanyl and morphine in rats: relevance for the side-effect liability of TTS-fentanyl. *J Pain Symptom Manage* 1998;15: 253-8.
126. Ahmedzai S, Allan E, Fallon M et al. Transdermal fentanyl in cancer pain. *J Drug Dev* 1994; 6: 93-7.
127. Slappendel R, Lako SJ, Crul BJP. Gastrointestinal side effects diminish after switch over from morphine to transdermal fentanyl [abstract no. P1004]. *Ann Oncol* 1994; 5 (Suppl 8): 200.
128. Meert TF. Pharmacotherapy of opioids: present and future developments. *Pharm World Sci* 1996; 18(1):1-15.
129. Hwang SS, Nichols KC, Southam MA. Transdermal permeation: physiological and physicochemical aspects. In: Lehmann KA, Zech D, ells. *Transdermal fentanyl*. Berlin: Springer, 1991;1-7.
130. Witham SL, Roy SD, Huang SS, Flynn GL. Concepts in transdermal delivery of narcotics. I. Enzymatic activity in the hairless mouse skin and human epidermal homogenates. *Pharm Res* 1986; 3: 54S.
131. Varvel JR, Shafer SL, Hwang SS et al. Absorption characteristics of transdermally administered fentanyl. *Anesthesiology* 1989; 70: 928-34.
132. Lehmann KA, Zech D. Transdermal fentanyl: clinical pharmacology. *J Symptom Pain Manage* 1992; 7: S8-16.
133. Gupta SK, Southam M, Gale R et al. System functionality and physicochemical model of fentanyl transdermal system. *J Pain Symptom Manage* 1992; 7 (Suppl):17-27.

134. Rung GW, Riemony S. The effect of skin temperature on transdermal fentanyl therapy [abstract]. *Anesth Analg* 1993; 76 (Suppl): 363.
135. Southam MA. Transdermal fentanyl therapy: system design, pharmacokinetics and efficacy. *Anti-cancer Drugs* 1995; 6 (Suppl 3): 29-34.
136. Esteve M, Levron JC, Flaisler B. Does aging modify pharmacokinetics of transdermal fentanyl [abstract]. *Anesthesiology* 1991; 75 (Supply: A705).
137. Thompson JP, Bower S, Rowbotham DJ. Perioperative pharmacokinetics of transdermal fentanyl in young and elderly patients. *British Pain Society Meeting*; 1996; Mar 28-29; Nottingham.
138. Portenoy RK, Southam MA, Gupta SA et al. Transdermal fentanyl for cancer pain. *J Am Soc Anesthesiol* 1993; 78: 36-43.
139. Southam M, Gupta B, Knowles N, Hwang SS. Transdermal fentanyl: an overview of pharmacokinetics, efficacy and safety. In: Lehmann KA, Zech D, eds. *Transdermal fentanyl*. Berlin: Springer, 1991; 107-16.
140. Milligan K, Haazen L, Bijmens L. Long-term efficacy and safety of transdermal fentanyl in the treatment of non-malignant pain: results from the interim analysis. Abstract presented at *Pain Management: Towards 2000*; November 1998; Israel.
141. Frymoyer JW, Cats-Baril WL. An overview of the incidence and costs of low back pain. *Orthop Clin North Am* 1991; 22: 263-71.
142. De Girolamo G. Epidemiology and social costs of low back pain and fibromyalgia. *Clin J Pain* 1991; 7 (Suppl 1 ): 1-7.
143. Borenstein D. Epidemiology, etiology, diagnostic evaluation, and treatment of low back pain. *Curr Opin Rheumatol* 1995; 7: 141-6.
144. Liu AC, Byrne F. Cost of care for ambulatory patients with low back pain. *J Fam Pract* 1995; 40: 449-55.
145. Deyo RA, Rainville J, Kent DI. What can the history and physical examination tell us about low back pain? *J Am Med Ass* 1992; 268: 760-5.
146. Koch H. The management of chronic pain in office-based ambulatory care: national ambulatory medical care survey. Advance data for vital and health statistics. No. 123, DHHS publication no., (PHS) 86-1250. Hyattsville (MD): Public Health Service, 1986.
147. Simpson RK, Edmondson EA, Constant CF, Collier C. Transdermal fentanyl as treatment for chronic low back pain. *J Pain Symptom Manage* 1997; 14: 218-24.
148. DelleMijn PLI, Duijn H van, Vanneste JAL. Prolonged treatment with transdermal fentanyl in neuropathic pain. *J Pain Symptom Manage* 1998; 16(4): 220-9.
149. Lebovits AH, Lefkowitz M, McCarthy D et al. The prevalence and management of pain in patients with AIDS: a review of 134 cases. *Clin J Pain* 1989; 5: 245-8.
150. Schofferman J. Care of the terminally ill person with AIDS. *Int Ophthalmol Clin* 1989; 29: 127-30.
151. Lewis MS, Warfield CA. Management of pain in AIDS. *Hosp Pract* 1990; 25: 51-4.
152. Barone JE, Wolkomir AF, Muakkassa FF, Fares LG. Abdominal pain and anorectal disease in AIDS. *Gastroenterol Clin North Am* 1988; 17: 631-8.
153. Gabuzda DH, Hirsch MS. Neurologic manifestations of infection with human immunodeficiency virus: clinical features and pathogenesis. *Ann Intern Med* 1987; 107: 383-91.
154. McArthur JC. Neurologic manifestations of AIDS. *Medicine* 1987; 66: 407-37.
155. Lange DJ, Britton CB, Younger DS, Hays AF The neuromuscular manifestations of human immunodeficiency virus infections. *Arch Neurol* 1988; 45: 1084-8.
156. Penfold J, Clark AJM. Pain syndromes in HIV infection. *Can J Anaesth* 1992; 39: 724-30.
157. Dixon P, Higginson I. AIDS and cancer pain treated with slow release morphine. *Postgrad Med J* 1991; 67 (Suppl 2): 92-4.
158. Lefkowitz M, Newshan G. An evaluation of the use of fentanyl transdermal system (Duragesic<sup>o</sup>) for chronic pain in patients with AIDS. Poster presentation at the *American Pain Society Meeting, 1997* and the *American Nurses in AIDS Conference, 1998*.